Integrated genomic and epigenomic analysis of circulating tumor DNA from hepatocellular carcinoma patients
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000041710
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Not provided
1. a history of malignancy (excluding intraepithelial cancer) with a disease-free period of 5 years or less. *1 2. Clinically diagnosed cancer of another organ. 3. the presence of multiple tumors for which different treatments of hepatic resection and ablation are contemplated for each. 4. Preoperative adjuvant therapy is contemplated prior to liver resection or ablation.*2 5.women who are pregnant or intend to become pregnant. 6. deemed unsuitable for enrollment in the study by the attending physician. *1 Even if the disease-free period is less than 5 years, a history of cancer with a 5-year relative survival rate equivalent to 95% or higher, such as stage I prostate cancer, stage 0 and stage I laryngeal cancer with complete response to radiotherapy, and the following pathological stages of cancer that have been completely resected, can be registered without exclusion. Gastric cancer (adenocarcinoma (general type)): stage 0-I, colon cancer (adenocarcinoma): stage 0-I, rectal cancer (adenocarcinoma): stage 0-I, esophageal cancer (squamous cell carcinoma, adenosquamous cell carcinoma, basal cell carcinoma): stage 0, breast cancer (non-invasive ductal carcinoma, non-invasive lobular carcinoma): stage 0, breast cancer (invasive ductal carcinoma, invasive lobular carcinoma, Paget's disease): stage 0-IIA Uterine cancer (endometrial adenocarcinoma, mucinous adenocarcinoma): stage IA, Prostate cancer (adenocarcinoma): stage I-II, Cervical cancer (squamous cell carcinoma): stage IA, Thyroid cancer (papillary carcinoma, follicular carcinoma): stage I, II, III, Renal cancer (panniculocarcinoma, anaplastic pigment cell carcinoma): stage I, Other intramucosal cancer equivalent lesions *2 Postoperative adjuvant therapy after liver resection or ablation is contemplated is acceptable.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive rates of LUNAR assay in stage IA-IIIA hepatocellular carcinoma
- Secondary Outcome Measures
Name Time Method